Pro Share Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Pro Share Advisors LLC

$36.7 Billion
Q1 2024

A detailed history of Pro Share Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 300,270 shares of VRTX stock, worth $142 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares

300,270

Previous 251,571 19.36%

Holding current value

$142 Million

Previous $102 Million 22.62%

% of portfolio

0.34%

Previous 0.32%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$407.69 - $446.08 $19.9 Million - $21.7 Million	48,699 Added 19.36%	300,270 $126 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $15.5 Million - $18.6 Million	-45,253 Reduced 15.25%	251,571 $102 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $11.9 Million - $12.8 Million	35,214 Added 13.46%	296,824 $103 Million
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $5.81 Million - $6.51 Million	-18,485 Reduced 6.6%	261,610 $92.1 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $7.03 Million - $8.02 Million	24,813 Added 9.72%	280,095 $88.2 Million

Q4 2022 Feb 02, 2023	SELL	$285.76 - $321.48 $7.55 Million - $8.5 Million	-26,430 Reduced 9.38%	255,282 $73.7 Million
Q3 2022 Nov 04, 2022	SELL	$273.83 - $305.53 $13.3 Million - $14.9 Million	-48,614 Reduced 14.72%	281,712 $81.6 Million
Q2 2022 Aug 01, 2022	SELL	$234.96 - $292.55 $37.3 Million - $46.4 Million	-158,650 Reduced 32.45%	330,326 $93.1 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $6.25 Million - $7.36 Million	-28,213 Reduced 5.46%	488,976 $128 Million
Q4 2021 Feb 08, 2022	BUY	$177.01 - $223.45 $25.5 Million - $32.2 Million	144,037 Added 38.6%	517,189 $114 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $6.08 Million - $6.8 Million	33,518 Added 9.87%	373,152 $67.7 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $950,386 - $1.12 Million	-5,069 Reduced 1.47%	339,634 $68.5 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $9.31 Million - $10.9 Million	44,967 Added 15.0%	344,703 $74.1 Million
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $7.67 Million - $10.2 Million	37,064 Added 14.11%	299,736 $70.8 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $8.91 Million - $10.6 Million	34,849 Added 15.3%	262,672 $71.5 Million
Q2 2020 Aug 03, 2020	BUY	$225.48 - $295.8 $6.16 Million - $8.08 Million	27,309 Added 13.62%	227,823 $66.1 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $17.1 Million - $21.2 Million	-85,641 Reduced 29.93%	200,514 $47.7 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $2.26 Million - $3.03 Million	13,551 Added 4.97%	286,155 $62.7 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $771,639 - $868,471	4,642 Added 1.73%	272,604 $46.2 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $4.72 Million - $5.45 Million	-28,653 Reduced 9.66%	267,962 $49.1 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $4.46 Million - $5.3 Million	27,238 Added 10.11%	296,615 $54.6 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $4.01 Million - $5.07 Million	26,403 Added 10.87%	269,377 $44.6 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $4.22 Million - $4.85 Million	-25,163 Reduced 9.38%	242,974 $46.8 Million
Q2 2018 Aug 13, 2018	SELL	$145.72 - $169.96 $6.93 Million - $8.08 Million	-47,540 Reduced 15.06%	268,137 $45.6 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $5.74 Million - $6.7 Million	37,852 Added 13.62%	315,677 $51.4 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $8.31 Million - $9.41 Million	60,520 Added 27.85%	277,825 $41.6 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $2.26 Million - $2.47 Million	15,247 Added 7.55%	217,305 $33 Million
Q2 2017 Aug 11, 2017	BUY	N/A	202,058	202,058 $26 Million

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Vertex Pharmaceuticals Inc Transaction History